These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23430528)

  • 1. Neonatal Bone Marrow Transplantation in MPS IIIA Mice.
    Lau AA; Shamsani NJ; Winner LK; Hassiotis S; King BM; Hopwood JJ; Hemsley KM
    JIMD Rep; 2013; 8():121-32. PubMed ID: 23430528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice.
    Lau AA; Hannouche H; Rozaklis T; Hassiotis S; Hopwood JJ; Hemsley KM
    Exp Neurol; 2010 Oct; 225(2):445-54. PubMed ID: 20673764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Engineered
    Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
    Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
    J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
    Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
    Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
    Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group.
    Köhn AF; Grigull L; du Moulin M; Kabisch S; Ammer L; Rudolph C; Muschol NM
    Mol Genet Metab Rep; 2020 Jun; 23():100578. PubMed ID: 32226768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
    Chen Y; Zheng S; Tecedor L; Davidson BL
    Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variables influencing fluorimetric
    Whyte LS; Hopwood JJ; Hemsley KM; Lau AA
    Mol Genet Metab Rep; 2015 Dec; 5():60-62. PubMed ID: 28652977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA.
    Crawley AC; Gliddon BL; Auclair D; Brodie SL; Hirte C; King BM; Fuller M; Hemsley KM; Hopwood JJ
    Brain Res; 2006 Aug; 1104(1):1-17. PubMed ID: 16828069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
    Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
    Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
    Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
    Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease.
    Sergijenko A; Langford-Smith A; Liao AY; Pickford CE; McDermott J; Nowinski G; Langford-Smith KJ; Merry CL; Jones SA; Wraith JE; Wynn RF; Wilkinson FL; Bigger BW
    Mol Ther; 2013 Oct; 21(10):1938-49. PubMed ID: 23748415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors.
    Lau AA; Hopwood JJ; Kremer EJ; Hemsley KM
    Mol Genet Metab; 2010 Jun; 100(2):168-75. PubMed ID: 20231109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
    Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
    Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector.
    Bobo TA; Samowitz PN; Robinson MI; Fu H
    Mol Ther Methods Clin Dev; 2020 Dec; 19():474-485. PubMed ID: 33313335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA).
    Hemsley KM; Hopwood JJ
    Behav Brain Res; 2005 Mar; 158(2):191-9. PubMed ID: 15698885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome.
    Lau AA; King BM; Thorsen CL; Hassiotis S; Beard H; Trim PJ; Whyte LS; Tamang SJ; Duplock SK; Snel MF; Hopwood JJ; Hemsley KM
    J Inherit Metab Dis; 2017 Sep; 40(5):715-724. PubMed ID: 28451919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.
    Langford-Smith A; Wilkinson FL; Langford-Smith KJ; Holley RJ; Sergijenko A; Howe SJ; Bennett WR; Jones SA; Wraith J; Merry CL; Wynn RF; Bigger BW
    Mol Ther; 2012 Aug; 20(8):1610-21. PubMed ID: 22547151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal Degeneration in MPS-IIIA Mouse Model.
    Intartaglia D; Giamundo G; Marrocco E; Maffia V; Salierno FG; Nusco E; Fraldi A; Conte I; Sorrentino NC
    Front Cell Dev Biol; 2020; 8():132. PubMed ID: 32195255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.